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Short summary  
The IMPrESS (International-MultiPlE-Sclerosis-Study) studied the significant impact of multiple 
sclerosis (MS) on the health and wellbeing of both people with the disease, and their caregivers, along 
with its broader socio-economic impact.  Results confirmed that there is an urgent need to achieve 
better outcomes for people with MS. This paper uses results from the IMPRESS to present new 
international evidence on the socio-economic burden of MS and discuss the merits of a likely paradigm 
shift in the management of MS towards the use of better (and more accurate) diagnostic follow-up to 
monitor disease progression and the earlier use of disease-modifying-treatments (DMTs) to achieve 
better clinical, quality of life and socio-economic results for individuals.  
 
  
  
Introduction 
Multiple-sclerosis (MS) is the most common cause of disability among central-nervous-system (CNS) 
diseases. MS is associated with a high cost of illness, both in terms of direct and indirect costs.  Given 
that the onset of MS is in early adult life (average onset at 29 years of age) lasting over an individual’s 
lifetime, there are huge costs relating to productivity losses. There is also a significant impact on the 
families of people with MS (PWMS).  
Treating until no-evidence-of-disease-activity (NEDA) is reached, including no relapses, no increase in 
disability and no new or active (enhancing) lesions on their MRI scans, is gaining more popularity1 and 
magnetic-resonance-imaging (MRI) is increasingly more use to diagnose and monitor disease activity 
in patients on treatment2.  Meeting this objective implies regular monitoring of not only clinical relapse 
and disability progression, but also MRI activity. However, regular use of MRI to monitor disease 
activity and the effects of treatment is still not universal, though it is increasingly used as an outcome 
measure for clinical trials.  
There are therapies, such as the disease-modifying-treatments (DMTs), which modify the course of 
the illness. However, considerable neurological damage (some of which may be permanent) can occur 
if PWMS are not given the appropriate treatment early enough. There is increasing focus on finding 
ways to identify disease progression as early as possible so that treatments can be adapted to prevent 
or delay further neurological damage2. There is evidence in the recent literature is advocating for an 
earlier treatments in multiple sclerosis3. The IMPrESS (International-MultiPlE-Sclerosis-Study)4 is the 
first study that: present the evidence for, and generate debate on, the merits of a policy change in the 
management of MS, including the use of better (and more accurate) diagnostic follow up to monitor 
disease progression and the earlier use of DMTs to achieve better outcomes for individuals; and also 
assess the socio-economic and personal impact of such a policy change compared to the current 
status. 
  
The IMPrESS (International MultiPlE Sclerosis Study)  
The IMPrESS used online surveys with PWMS, their caregivers and clinicians as well as secondary data 
from the literature and health-technology-assessment (HTA) to produce new international evidence 
on: the socio-economic burden and health-related-quality-of-life (HRQoL) of people affected by MS; 
the impact that a paradigm shift in the management of MS could have on health outcomes and 
resource utilisation; the views of PWMS and treating physicians and to explore the factors which 
influence these views; the criteria driving value assessments of MS pharmaceutical treatments by 
analysing HTA recommendations and their impact across different settings. This paper summarises 
the new findings from the surveys and HTA analysis; more details are presented elsewhere4. Data 
  
presented here refers to a larger sample of responses including an additional wave of data collection 
completed after the publication of the project report4 (see T 1 and 2). 
 
Primary data collection from PWMS, their caregiver and clinicians 
Costs (table 1) - The primary analysis of the PWMS and caregiver data sets provided updated 
international data on the burden of MS they experience as well as their experience of treatment and 
support when novel DMTs are available in clinical practice. Total average annual PWMS costs were 
€41,212 (SD € 18,761).  Just over half of total average costs (€21,563) were associated with direct 
medical costs, followed by indirect costs (€17,492) and direct non-medical costs (€2,157).  The overall 
costs (and relative ratio between direct and indirect costs) varied also according to the type of MS and 
severity of the disease. More severe and disabling cases of secondary-progressive-MS (SPMS) were 
characterised by increased total costs (€49,070) where indirect costs accounted for the majority 
(about 65%) compared with relapsing–remitting-MS (RRMS; about €41914) where indirect costs 
accounted for about 36%. Similar results are available elsewhere5,6. Caregiver costs related to 
productivity losses are about double the cost reported by PWMS (€31,653 vs. €16,318).  More data 
according to type of MS and treatment delays are in appendices 1-4. 
 
Quality of life and how they feel (table 1) - The average utility value reported was 0.56 [56% of perfect 
health] based on EuroQol-5-dimensions-5-levels (EQ-5D-5L), with a loss of 28% compared with the 
general population. Utilities varied across healthcare systems and types of MS. Comparable estimates 
were found elsewhere6-7. Greater values in utility were accompanied by lower disability and increased 
satisfaction values with the healthcare service received. Fatigue and weakness, bladder or balance 
problems were the most frequently reported factors that had a significant impact on PWMS life and 
they believed a new MS treatment should keep them under control. It can be argued that other health 
state factors beyond EQ-5D-5L are (more) important to PWMS (appendix 5). Evidence from the 
literature7 showed that MS-related complications, including severe urinary tract infections, 
constipation, fractures and falls (due to increased weakness and fatigue), and pressure sores are major 
reasons for hospital admissions with significant socioeconomic consequences. This highlights the 
importance of identifying the most appropriate utility measure to be adopted. Caregivers reported 
better quality of life compared with PWMS (73% vs. 59% of perfect health), whereas both caregivers 
and the person they are caring for reported a mild level of discomfort/disability. 
 
Exploring the impact that a paradigm shift in the management of MS could have on health outcomes 
and resource utilisation - Subgroup analysis compared individuals who received early diagnosis of MS 
  
(≤12 months from first symptoms) with individuals who received diagnosis later than 12 months after 
the first symptoms1. Analysis of the data collected from the PWMS showed that patients treated 
earlier in the course of the disease showed a trend towards lower total (€39,037vs. €42,996), indirect 
(€15,733 vs. €18,934) and DMT (€19,364 vs. €20,491) costs and a higher EQ5D score (0.62 vs. 0.56; 
p<0.01) compared to those receiving late treatment. More in appendices 1-4. 
 
Experience of MS - The majority of PWMS had experience of MS treatment with DMTs from the start 
of their treatment (80%; 685/856); about 38% of the PWMS were currently receiving DMTs (325/856). 
Results were comparable with USA data8. PWMS were aware of the potential side effects of treatments 
and may prefer to delay possible risks as much as possible; however when they discussed the 
irreversible effect of MS on brain volume and the attached disabilities with their clinician they may opt 
for an early intervention. The preferred source of information for PWMS were the internet (MS-specific 
sites) and clinicians; this is also confirmed in the literature8. Although this population was approached 
online and may be expected to use online resources, only a few of them reported online support 
groups, social media or online forums as preferred source of information (less than 30% for each type 
of source). 
Both clinicians and patients reported delays between first symptoms and diagnosis (table 2). Patients 
presented mixed views on the outcomes of being treated before receiving diagnosis (avoiding 
unnecessary disability vs. receiving wrong treatment). Although early treatment after diagnosis to 
maintain NEDA is gaining support as appropriate practice, clinical approaches vary across physician-
respondents.  Similar key factors of effectiveness, tolerability and safety drive treatment more than 
costs, route of administration and convenience for both groups. They all recognised that there is more 
to disease activity than just relapse/disability progression. Results from the PWMS survey showed that 
half of the respondents preferred to make the final decision about their management of care. Whether 
a PWMS becomes engaged in their care is a choice for the individual, but clinicians recognise that this 
should be strongly promoted given the derived health benefits to the PWMS and their increased 
satisfaction8. 
 
Analysis of HTAs for MS therapies and the factors influencing decision-making in different settings 
New comparative evidence from the HTA assessments on 8 different MS treatments2 conducted 
                                                          
1 The cut-off of 12 months adopted here followed current guidance recommending that initiation of a DMT 
within 12 months of a single neurological attack with MRI-enhancing lesions should be considered as a 
promising, preventative strategy against future accumulation of disability1-2. 
2 IFNβ 1a IM (Avonex), alemtuzumab (Lemtrada), IFNβ 1a SC (Rebif), glatiramer acetate (Copaxone), 
teriflunomide (Aubagio), dimethyl fumarate (Tecfidera), fingolimod (Gilenya), natalizumab (Tysabri). 
  
across country settings (England, Scotland, Sweden, France, Germany and Canada – see appendix 6 
and [4]) showed that there is a need for a standardized approach in HTA decision making when 
including PWMS’ views and a wide range of evidence and outcomes must be considered. Greater 
homogeneity across HTA bodies is needed when taking into account HRQoL data and they should 
include dimensions that patients say have a significant impact on their daily lives but they are not 
captured by the generic tools (such as EQ-5D-5L) usually adopted by HTA agencies. The lack of real 
world data on the clinical and economic benefits of the technology is a key issue commonly reported 
by HTA bodies9. The collection of long-term benefit of DMTs using real world evidence is a necessary 
step forward (and currently underway), but should not cause delays to HTA decision-making. Crucially, 
discussion on an earlier use of DMTs to reduce accumulation of irreversible long term damage and 
decrease socioeconomic burden is currently missing from HTA assessment. 
 
Conclusion 
The IMPRESS findings demonstrate the need for a comprehensive policy discussion to tackle the 
problem of improving health outcomes for people with MS.10 The evidence suggests that this is 
possible if policy makers address a series of issues to secure the following three main goals: (1) 
improve the quality of care and health outcomes for every person with MS; (2) generate further robust 
evidence to inform decision making; (3) increase responsiveness of health care systems to new 
evidence on MS. 
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Table 1: The primary analysis of the PWMS and caregiver data sets (costs, quality of life, and how 
they feel)  
 Caregivers (n= 265) 
Mean (SD) 
PWMS (n= 856) 
Mean (SD) 
Total annual direct medical costs n/a €21,093 (€13,317) 
Total annual direct non-medical costs n/a €2,110 (€587) 
Total annual indirect costs €31,653  
(33,475)  
€16,318  
(4910) 
EQ-5D-5L utility 0.73 (0.20) 0.59  (0.28)  
How they feel/level of disability The majority of the 
caregivers felt no or mild 
burden because of their 
status as caregiver  
(Zarit score=5.98) 
The majority of PWMS 
reported low levels of 
disability  
(Barthel index=16.95) 
Note: An observational study of adults with MS (at all levels of self-reported disease severity) and their 
caregivers was administered through anonymous online surveys available in 21 different countries. 
Recruitment was facilitated by national and international MS organisations and MS-centres; about 40 
organisations/centres approached (about 73%) supported the dissemination of the online survey in 
English and/or local languages. The organisation/centres approached included 21 different countries 
(Australia, Canada, Czech republic, Croatia, Estonia, France, Germany, Greece, Italy, Poland, Portugal, 
Romania, Russia, Serbia, Slovenia, Spain, Sweden, the Netherlands, UK, USA) and responses were 
collected from individuals resident in 34 different nations. The majority of responses were collected 
from Australia, Croatia, France, Greece, Italy, Poland, Romania, Serbia, Slovenia, Spain, UK, USA (>2% 
from each individual country). The notal number of PWMS questionniares returned was 1152 (856 
were considered suitable for analysis). The surveys captured data on: direct medical costs (medication 
costs, visits, hospitalisation); direct non-medical costs (help from caregivers); indirect costs 
(productivity loss); PWMS and their caregiver health-related quality of life HRQoL (EuroQol-5-
dimensions-5-levels, EQ-5D-5L); PWMS disability (Barthel-Index); their satisfaction with the treatment 
received (Likert scale from 0-not satisfied - to 10 – very satisfied); burden among caregivers (Zarit 
Burden Interview). Additional information on the PWMS data (Access to medicines and 
hospitalization, Access to informal care, Quality of life and disability, and Productivity lost) according 
to type of MS and treatment delays are available from electronic appendices (1-5). 
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Table 2: Clinician and PWMS experience of MS 
 What clinicians said 
(n=49) 
What PWMS said 
(n=856) 
Diagnosis and treatment   
When their patients/they 
themselves experienced the first 
MS symptom  
70% -the majority of their 
patients experienced the 
first MS symptom aged 20-
30 years  
30.02 years old (mean) 
Age at diagnosis of most patients 25% - 31-40 years old 
75% - 20-30 years old 
34.5 years old (mean) 
Delay between first symptoms 
and MS diagnosis  
37.5% - 1 year or more  5.1 years (mean) 
Delay between diagnosis and 
treatment with DMTs 
86.7% - Within 6 months  1.9 years (mean) 
Treatment with DMTs   
Choosing DMTs: the most 
important three attributes are… 
Effectiveness  
Safety 
Tolerability 
Convenience (25%) 
Doctor’s advice (19%) 
Other* (19%) 
Tolerability (17%) 
Effectiveness (14%) 
Treating PWMS with oral DMTs  75% were treating their 
patients with oral DMTs 
54.9% were treated with 
DMTs 
Switching DMTs  For 57% of respondents the 
waiting time before 
switching the patients to 
another first- or second-line 
DMT may vary according to 
the clinical situation of the 
PWMS 
31% switched from one 
DMT to another 
Note: A separate online survey (supplemented by face-to-face/telephone discussions) from the PWMS 
(see table 1) was designed to collect information from clinicians about their experience of MS 
treatment and support. The target group was MS expert physicians across the participating countries 
who were approached via personal contacts and patient organisations. A series of MS specialists 
participating in the conference of the European Association of Neurologist 2015 were also invited to 
participate. Clinicians’ countries of practice included: Croatia, Denmark, France, Germany and Greece, 
Italy, Poland, Russia, Spain, Switzerland, the Netherlands, UK, USA (the total number of questionnaires 
returned was 94; 49 were suitable for analysis); the PWMS survey was disseminated in Australia, 
Canada, Czech republic, Croatia, Estonia, France, Germany, Greece, Italy, Poland, Portugal, Romania, 
Russia, Serbia, Slovenia, Spain, Sweden, the Netherlands, UK, USA (1152 questionnaires returned; 856 
were suitable for analysis). 
 
Supplementary material (Electronic appendices)  
 
Appendix 1 socio-demographic and clinical sample characteristics 
     Frequency Percent 
Age 
mean (sd) 45.49 69.082 
Gender 
Male 199 23.2 
Type of MS Relapsing remitting MS (RRMS) 542 65.6 
  Secondary Progressive MS (SPMS)  110 13.3 
  Primary Progressive MS (PPMS)  61 7.4 
  I’m not sure  113 13.7 
Marital status Single 221 26.1 
  Married or cohabiting  514 60.6 
  Divorced  71 8.4 
  Separated 31 3.7 
  Widow 11 1.3 
Level of education Primary 29 3.5 
  Secondary School Certificate  110 13.1 
  A levels  208 24.8 
  University 407 48.5 
  others 53 6.3 
  none 33 3.9 
At what age did you first 
experience MS symptoms? (years) 
mean (sd) 
30.0 69.0 
At what age were you diagnosed 
with MS? (years) 
mean (sd) 
34.5 68.7 
Delay between first symptoms and 
diagnosis (years) mean (sd) 5.1 8.2 
When do you think the treatment 
should be started? 
When you first experience symptoms that are 
likely to be due to MS (that is, before you are 
formally diagnosed with MS)  
270.0 32.9 
  After being diagnosed with MS 550.0 67.1 
Utility  EQ-5D5L score 0.6 0.3 
Severity  Barthel score 17 4.1 
 Severe dependence (Barthel score<=15) 168 23.8 
 Moderate dependence (Barthel score 16-17) 122 17.3 
 Slight dependence (Barthel score 18-19) 165 23.3 
 Independent (Barthel score 20) 252 35.6 
 
  
Appendix PWMS - Access to medicines and hospitalisation 
 
PWMS treated earlier (starting treatment within 12 months after a first symptom if MRI establishes 
evidence of MS diagnosis  (compared with more than 12 months)  showed a trend towards being on 
oral DMT (20% vs 14%; P<0.05). Patients treated earlier showed no change in hospital admissions. 
More severe PWMS were less likely to access DMTs but were more likely to be hospitalised (P<0.05). 
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Appendix 2 PWMS - Access to informal care 
 
PWMS treated earlier showed no change in access to informal care (compared with individuals 
starting treatment more than 12 months after diagnosis). Levels of access to informal care was 
correlated to the severity of the disease (p<0.05). 
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Appendix 3 - PWMS - Quality of life and disability 
 
 
Note: Utility loss (compared with general population) 
PWMS treated earlier in the course of the disease showed a trend towards higher EQ5D utility score. 
PWMS. EQ5D utility score was inversely correlated to the severity of the disease (p<0.05). 
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Appendix 4 PWMS - Productivity lost 
 
Note: Frequencies reported here refer to positive responses to the question “The fact that you are 
affected by the disease led to any work-related problems in the last 6 months?”. PWMS treated 
earlier in the course of the disease reported less work-related issues compared with individuals 
starting treatment more than 12 months after diagnosis (30% vs 42%; p<0.05). Productivity loss was 
correlated to the severity of the disease (p<0.05). 
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Appendix 5 PWMS - Most commonly quality of life aspects, not captured by the EQ-5D 
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Appendix 6 – HTA - Treatment recommendations for MS  
Molecule name 
(branded name) 
Indication 
considered 
Evidence from HTA agencies 
  NICE 
(UK) 
TLV 
(Sweden) 
HAS 
(France) 
SMC 
(Scotland) 
IQWIG 
(Germany) 
CADTH 
(Canada) 
IFNβ 1a IM 
(Avonex) 
RRMS DNL DNL LWC LWC N/A N/A 
Alemtuzumab 
(Lemtrada) 
Active relapsing–
remitting multiple 
sclerosis 
L L N/A L N/A DNL 
IFNβ 1a SC 
(Rebif) 
RRMS DNL L LWC DNL N/A DNL 
IFNβ 1b SC 
(Betaferon, 
Extavia) 
RRMS N/A L LWC N/A N/A N/A 
Glatiramer 
acetate 
(Copaxone) 
RRMS DNL N/A L N/A N/A N/A 
Teriflunomide 
(Aubagio) 
RRMS LWC L L LWC A DNL 
Dimethyl 
fumarate 
(Tecfidera) 
Active relapsing-
remitting multiple 
sclerosis 
LWC LWC LWC L A N/A 
Fingolimod 
(Gylenia) 
Highly active 
relapsing–remitting 
multiple sclerosis 
LWC L LWC LWC A LWC 
Natalizumab 
(Tysabri) 
Rapidly evolving 
severe relapsing–
remitting multiple 
sclerosis (RES). 
L L LWC DNL N/A LWC 
Notes: RRMS=relapsing remitting multiple sclerosis; L= Listed (accepted); LWC= Listed with criteria (restricted); DNL= Do not list (rejected); 
A= assessed without decision. N/A = not appraised for the indication; NICE=National Institute for Health and Care Excellence (England); 
TLV=Dental and Pharmaceutical Benefits Board (Sweden); HAS=Haute Autorité de Santé (France); SMC=Scottish Medicines Consortium 
(Scotland); IQWiG=Institute for Quality and Efficiency in Healthcare (Germany); CADTH=Canadian Agency for Drugs and Technologies in 
Health (Canada). 
 
